The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making

I Whitehead,G W Irwin,F Bannon,C E Coles,E Copson,R I Cutress,R V Dave,M D Gardiner,M Grayson,C Holcombe,S Irshad,C O'Brien,R L O'Connell,C Palmieri,A M Shaaban,N Sharma,J K Singh,S Potter,S A McIntosh,NeST Study Research Collaborative,Liz Clayton,Ellen Copson,Karina Cox,Tim Crook,Beatrix Elsberger,Ahmed Ghoneima,Sirwan Hadad,Anita Hargreaves,Paul Healy,Adam Heetun,Dan Henderson,Julia Henderson,Natalie Hirst,Fiona Hoar,Mike Hughes,Emma Iddles,Sheeba Irshad,Tracey Irvine,Stacey Jones,Sarantos Kaptanis,Emma MacInnes,Andrew McCanny,Linda McLaughlin,Anthony Neal,Rachel O'Connell,Neill Patani,Belinda Pearce,Mandana Pennick,Simon Pilgrim,Rene Roux,Matthew Rowland,Sunita Saha,Kavita Sharma,Jagdeep Singh,Chiara Sirianni,Brendan Skelly,Rachel Soulsby,Mark Tatterton,Rob Thomas,Medy Tsalic,Raghavan Vidya,Olivia Waker,Lisa Whisker,Ian Whitehead,Janet Woods

DOI: https://doi.org/10.1186/s12885-020-07757-6

IF: 4.638

2021-01-22

BMC Cancer

Abstract:Background: Neoadjuvant systemic therapy (NST) is increasingly used in the treatment of breast cancer, yet it is clear that there is significant geographical variation in its use in the UK. This study aimed to examine stated practice across UK breast units, in terms of indications for use, radiological monitoring, pathological reporting of treatment response, and post-treatment surgical management. Methods: Multidisciplinary teams (MDTs) from all UK breast units were invited to participate in the NeST study. A detailed questionnaire assessing current stated practice was distributed to all participating units in December 2017 and data collated securely usingREDCap. Descriptive statistics were calculated for each questionnaire item. Results: Thirty-nine MDTs from a diverse range of hospitals responded. All MDTs routinely offered neoadjuvant chemotherapy (NACT) to a median of 10% (range 5-60%) of patients. Neoadjuvant endocrine therapy (NET) was offered to a median of 4% (range 0-25%) of patients by 66% of MDTs. The principal indication given for use of neoadjuvant therapy was for surgical downstaging. There was no consensus on methods of radiological monitoring of response, and a wide variety of pathological reporting systems were used to assess tumour response. Twenty-five percent of centres reported resecting the original tumour footprint, irrespective of clinical/radiological response. Radiologically negative axillae at diagnosis routinely had post-NACT or post-NET sentinel lymph node biopsy (SLNB) in 73.0 and 84% of centres respectively, whereas 16% performed SLNB pre-NACT. Positive axillae at diagnosis would receive axillary node clearance at 60% of centres, regardless of response to NACT. Discussion: There is wide variation in the stated use of neoadjuvant systemic therapy across the UK, with general low usage of NET. Surgical downstaging remains the most common indication of the use of NAC, although not all centres leverage the benefits of NAC for de-escalating surgery to the breast and/or axilla. There is a need for agreed multidisciplinary guidance for optimising selection and management of patients for NST. These findings will be corroborated in phase II of the NeST study which is a national collaborative prospective audit of NST utilisation and clinical outcomes.